Amarin Corp Plc (AMRN)

[ziploc_1]

Sluicebox and PDude...You're right!...All the issues brought up by Nice were also brought up the FDA in the Adcom of 2018...and the vote was 16 to zero in favor of approving Vascepa for the CVD indication...also, the use of Vascepa in millions of patients since then has only strengthened the case for its life saving efficacy and for its side effects being benign.

The Nice meeting seem to be setting the groundwork for a debate on the price that the U.K. National health service will pay for Vascepa.

Nevertheless, we need to be better prepared for a skirmish than we were at Nice.